Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | PRKCA | P17252 | 2/20 | 0.36 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.36 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.35 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | BAK1 | Q16611 | 1/20 | 0.34 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.33 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.33 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.33 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18525122 | 0.88 | PTPN1 (0.42) | PTPN1GLRA1MRGPRX4LMNAHPGD | |
| SCHEMBL9287286 | 0.88 | PTPN1 (0.40) | PTPN1PRKCAPRKCDGLRA1MRGPRX4 | |
| SCHEMBL20803895 | 0.87 | PTPN1 (0.42) | PTPN1GLRA1MRGPRX4LMNAHPGD | |
| SCHEMBL18750612 | 0.86 | PTPN1 (0.40) | PTPN1PRKCAPRKCDGLRA1LMNA | |
| SCHEMBL9278579 | 0.84 | PTPN1 (0.38) | PTPN1PRKCAPRKCDGLRA1LMNA | |
| SCHEMBL9283033 | 0.79 | PTPN1 (0.40) | PTPN1GLRA1MRGPRX4LMNAHPGD | |
| SCHEMBL12108742 | 0.78 | PTPN1 (0.42) | PTPN1GLRA1MRGPRX4LMNAHPGD | |
| SCHEMBL9285361 | 0.78 | MCL1 (0.41) | PTPN1PRKCAPRKCDGLRA1MRGPRX4 | |
| SCHEMBL20370139 | 0.78 | PTPN1 (0.45) | PTPN1LMNAHPGDMAOB | |
| SCHEMBL18525117 | 0.78 | PTPN1 (0.40) | PTPN1GLRA1MRGPRX4LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170044160-A1 | TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS, INC. | 2017-02-16 | — | — | US | disclosed |
| US-9315451-B2 | Tetracycline compounds | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2016-04-19 | — | — | US | disclosed |
| US-20120135968-A1 | Tetracycline Compounds | TETRAPHASE PHARMACEUTICALS, INC. | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044160-A1 | TETRACYCLINE COMPOUNDS | TUBB, TUBA1C, TUBA1A | PTPN1 402/4885PRKCA 4379/4885PRKCD 4247/4885 |
| US-20120135968-A1 | Tetracycline Compounds | TUBB, TUBA1C, TUBA1A | PTPN1 402/4885PRKCA 4379/4885PRKCD 4247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.